Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

Epistaxis are present in over 90 % of patients with Rendu - Osler . They involve no significant difference 2 sexes. They often appear in childhood and adolescence and are present in three-quarters of patients at the age of 20 years. These epistaxis increasing in frequency and volume to the age of 60 in 2/3 of patients. Epistaxis are spontaneous , repetitive and recurring . They are highly variable in duration, intensity and frequency of occurrence . Some patients may have more than 40 monthly episodes with mean duration of 5 minutes of bleeding and chronic anemia and can sometimes acute anemia with transfusions need to be source. These epistaxis stigmatize patients and inevitably affect their quality of life and social skills . The various proposed ( cauterization , intra- mucosal injections, laser selective hémostatses , embolization or surgical dermoplasties ) allow for some short-term remissions . Bevacizumab is an antiangiogenic use in the treatment of colorectal cancers . It is also used in ophthalmology intravitreal to reduce vascular proliferation in glaucoma retinopathy and certain corneal neovascularization. In 2009, Prithviraj reported the use of bevacizumab injection to treat pulmonary arteriovenous malformations in a patient with Rendu - Osler . The result is doubly interesting including a saving action on epistaxis which decrease in frequency and duration. This communication prompted the authors to focus more on this medication. The product has been used in local submucosal injection intranasal laser was coupled with satisfactory results objectified by a decrease in the number of epistaxis , reducing blood transfusions and improved social lives. The use of local instillation bevacuzimab represents a way forward for the treatment of these epistaxis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Telangiectasia, Hereditary Hemorrhagic Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Epistaxis Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Hemostatic Disorders Nose Diseases Otorhinolaryngologic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory Telangiectasis Vascular Diseases Vascular Malformations

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

CHU de Caen

Caen, 14033, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with Rendu-Osler-Weber disease
patients with iterative epistaxis (at least 10 per month)
patients without treatment for 3 months with usual techniques (for the epistaxis)
patients speaking french fluently
patients with written consents
affiliation to social security
women with effective contraception during the treatment and for 6 months after stopping

Exclusion criteria

General criteria:

Pregnant women, breastfeeding
Hypersensitivity to the active substance or any of its excipients
Hypersensitivity to the products of Chinese hamster ovary cells or other human or humanized recombinant antibodies
Inability to undergo medical monitoring due to reasons geographical, social or psychological
Patient under guardianship
Patient included in another biomedical research protocol

Related to medical history criteria:

Uncontrolled hypertension ( systolic BP > or = 150 mmHg and / or Diastolic BP > or = 100 mmHg)
Thrombocytopenia <100 G / L
Taking NSAIDs within ten days prior to inclusion
Anticoagulant therapy or thrombolytic within 28 days before inclusion
Tumor, genetic predisposition to bleeding, coagulopathy , patient receiving treatment full anticoagulant dose for an event thromboembolism prior to inclusion
Major surgery within 28 days prior to inclusion
History of thromboembolic disease within 6 months prior to enrollment
Arteriovenous malformation localized to the brain, liver or lung on scanner older than 5 years
History of heart failure
Patients with proteinuria / creatinine greater than 2g / g

Treatment and study plan

bevacuzimab spray

Drug

Primary outcomes

decrease of at least 50% of number of epistaxis in a month compared to the month before inclusion.

Time frame: one month

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: EROSB

Important dates

Study start: 2014
Primary completion: 2020
Study completion: 2021
First posted: Jun 6, 2014
Registry last updated: Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed